Study guide

16.4 Multiple Sclerosis & Central Demyelinating Diseases

MRCP UK

Track your progress as you read

Finished sections get a check mark.

1 MRCP(UK) Part 1: Exam Overview, Blueprint & Strategy

1.1 Part 1 Format, Delivery and Fees 1.2 The Official Blueprint and Mark Allocation 1.3 Scaled Scoring, Attempt Limits and Best-of-Five Technique

2 Clinical Sciences: Cellular, Genetic & Molecular Medicine

2.1 Organelles, Cytoskeleton & Membrane Transport 2.2 Cell Cycle Control, Apoptosis & Cell Signalling 2.3 Mendelian & Non-Mendelian Inheritance 2.4 Trinucleotide Repeat Disorders & Chromosomal Abnormalities 2.5 Purine, Pyrimidine Metabolism & the Porphyrias 2.6 Glycogen, Lipid Storage & Amino Acid Disorders

3 Clinical Sciences: Anatomy, Physiology & Immunology

3.1 Clinical & Cross-Sectional Anatomy 3.2 Systemic Clinical Physiology & Homeostasis 3.3 Clinical Immunology & Hypersensitivity Reactions

4 Clinical Sciences: Statistics, Epidemiology & Trial Design

4.1 Study Designs & Evidence Hierarchy 4.2 Diagnostic Testing, Screening & Predictive Values 4.3 Statistical Analysis & Risk Quantification

5 Clinical Pharmacology, Therapeutics & Toxicology

5.1 Pharmacokinetics & Pharmacodynamics 5.2 Cytochrome P450 Systems & High-Risk Drug Interactions 5.3 Adverse Drug Reactions & Therapeutic Drug Monitoring 5.4 Paracetamol & Salicylate Poisoning 5.5 Toxidromes, Antidotes, Carbon Monoxide & Toxic Alcohols

6 Cardiology: Coronary Artery Disease & Heart Failure

6.1 Acute Coronary Syndromes & Myocardial Infarction 6.2 Heart Failure & Cardiomyopathies 6.3 Cardiac Assessment & ECG Interpretation

7 Cardiology: Arrhythmias, Valvular & Pericardial Disease

7.1 Atrial Fibrillation, Narrow & Broad Complex Tachycardias 7.2 Bradyarrhythmias, Conduction Block & Antiarrhythmic Drugs 7.3 Valvular Heart Disease & Murmur Interpretation 7.4 Infective Endocarditis 7.5 Pericardial & Acute Aortic Diseases

8 Respiratory Medicine: Airway & Parenchymal Lung Disease

8.1 Asthma: Diagnosis, Chronic Management & Acute Attacks 8.2 COPD: GOLD Staging, Stable Management, Exacerbations & NIV 8.3 Interstitial Lung Disease & Sarcoidosis 8.4 Respiratory Infections & Bronchiectasis

9 Respiratory Medicine: Vascular, Pleural & Sleep Disorders

9.1 Venous Thromboembolism & Pulmonary Embolism 9.2 Pleural Effusion & Pneumothorax 9.3 Respiratory Failure & Sleep-Disordered Breathing

10 Gastroenterology: Luminal Gastrointestinal Disease

10.1 GORD, Barrett's Oesophagus & Oesophageal Motility Disorders 10.2 Peptic Ulcer Disease, Helicobacter pylori & Zollinger-Ellison Syndrome 10.3 Crohn's Disease, Ulcerative Colitis & Extraintestinal Manifestations 10.4 IBD Medical Therapy, Coeliac Disease & Malabsorption 10.5 Acute Upper Gastrointestinal Bleeding: Risk Scores, Ulcer & Variceal Haemorrhage 10.6 Lower Gastrointestinal Disorders & Colonic Neoplasia

11 Gastroenterology: Liver, Biliary & Pancreatic Disease

11.1 Viral Hepatitis A to E 11.2 Autoimmune Hepatitis & Metabolic Liver Disease 11.3 Cirrhosis & Complications of Portal Hypertension 11.4 Cholestatic Liver Disease: PBC and PSC 11.5 Gallstone Disease, Biliary Sepsis & Pancreatitis

12 Endocrinology & Diabetes: Diabetes & Thyroid

12.1 Diabetes: Diagnostic Thresholds, Classification & Pathophysiology 12.2 NICE-Directed Type 2 Therapy & Microvascular Complications 12.3 Acute Diabetic Emergencies (DKA & HHS) 12.4 Thyrotoxicosis, Thyroiditis & Management of Hyperthyroidism 12.5 Hypothyroidism, Subclinical Disease & Thyroid Nodules

13 Endocrinology & Diabetes: Adrenal, Pituitary & Calcium

13.1 Hypopituitarism, Pituitary Apoplexy & Hyperprolactinaemia 13.2 Acromegaly, Diabetes Insipidus & SIADH 13.3 Cushing's Syndrome: Aetiology, Screening & Localisation 13.4 Adrenal Insufficiency & Endocrine Hypertension 13.5 Calcium Regulation & Hypercalcaemia 13.6 Hypocalcaemia & Metabolic Bone Disease

14 Renal Medicine: AKI, Glomerular & Tubulointerstitial Disease

14.1 Acute Kidney Injury & Chronic Kidney Disease 14.2 Nephrotic and Nephritic Syndromes & Primary Glomerular Disease 14.3 Rapidly Progressive Glomerulonephritis 14.4 Tubulointerstitial & Inherited Renal Diseases

15 Renal Medicine: Fluid, Electrolytes & Acid-Base Balance

15.1 Sodium & Water Disorders 15.2 Potassium, Magnesium & Phosphate Disorders 15.3 Acid-Base Disorders & Blood Gas Analysis

16 Neurology: Cerebrovascular, Headache & Demyelinating Disease

16.1 Stroke Classification, Brainstem Syndromes & Hyperacute Reperfusion 16.2 Secondary Prevention, TIA, Carotid Surgery & Intracranial Haemorrhage 16.3 Headache Disorders & Cranial Neuralgias 16.4 Multiple Sclerosis & Central Demyelinating Diseases

17 Neurology: Epilepsy, Movement Disorders & Neuromuscular Disease

17.1 Epilepsy & Acute Seizures 17.2 Movement Disorders & Cognitive Impairment 17.3 Neuromuscular Junction & Peripheral Nerve Disorders

18 Rheumatology: Inflammatory Arthritis & Connective Tissue Disease

18.1 Rheumatoid Arthritis: Pathophysiology, Clinical Features & Diagnosis 18.2 DMARDs, Biologics & Their Toxicities 18.3 Seronegative Spondyloarthropathies 18.4 Systemic Lupus Erythematosus & Drug-Induced Lupus 18.5 Systemic Sclerosis & Scleroderma Renal Crisis 18.6 Sjogren's Syndrome & Inflammatory Myopathies

19 Rheumatology: Systemic Vasculitis & Crystal Arthropathy

19.1 Vasculitis Classification, Large and Medium Vessel Disease 19.2 ANCA-Associated and Immune Complex Small Vessel Vasculitis 19.3 Gout & Calcium Pyrophosphate Deposition Disease

20 Infectious Diseases & Tropical Medicine

20.1 Sepsis-3 Definitions & the Sepsis Six 20.2 Bacterial Meningitis, CSF Interpretation & Toxic Shock Syndrome 20.3 Tuberculosis: Pathogenesis & Clinical Manifestations 20.4 Tuberculosis: Diagnosis & Anti-Tuberculous Therapy 20.5 HIV Infection & Opportunistic Diseases 20.6 Malaria: Species, Life Cycle & Severe Disease 20.7 Enteric Fever, Arboviral Infection & Tissue Parasites

21 Haematology: Anaemias & Red Cell Disorders

21.1 MCV-Based Diagnostic Approach to Anaemia 21.2 Haemolytic and Autoimmune Haemolytic Anaemias 21.3 Membranopathies, Enzymopathies, PNH & Sickle Cell Disease

22 Haematology: Malignancy, Coagulation & Transfusion Medicine

22.1 Acute Leukaemias 22.2 Chronic Leukaemias & Myeloproliferative Neoplasms 22.3 Lymphomas & Plasma Cell Dyscrasias 22.4 Coagulation Cascade & Inherited Bleeding Disorders 22.5 Thrombocytopenia & Thrombotic Microangiopathies 22.6 Transfusion Products & Acute Transfusion Reactions

23 Psychiatry in General Medicine

23.1 Mood & Psychotic Disorders in Medical Patients 23.2 Psychiatric Emergencies & Substance Misuse 23.3 Mental Capacity & UK Mental Health Law

24 Geriatric Medicine

24.1 Comprehensive Geriatric Assessment, Frailty, Delirium & Falls 24.2 Polypharmacy, Deprescribing & Pressure Ulcers

25 Dermatology

25.1 Inflammatory Skin Disease, Immunobullous Disorders & Severe Drug Eruptions 25.2 Cutaneous Malignancy

26 Oncology & Palliative Medicine

26.1 Neutropenic Sepsis, Spinal Cord Compression & SVC Obstruction 26.2 Hypercalcaemia of Malignancy & Tumour Lysis Syndrome 26.3 Palliative Care & End-of-Life Symptom Control

27 Medical Ophthalmology

27.1 The Acute Red Eye & Sudden Painless Visual Loss 27.2 Retinopathy in Systemic Disease

16.4 Multiple Sclerosis & Central Demyelinating Diseases

Key Takeaways Explain This Topic AI

The McDonald criteria were revised in 2024 (published in The Lancet Neurology, September 2025) and add the optic nerve as a fifth anatomical region for dissemination in space.

Oligoclonal bands present in cerebrospinal fluid but absent in paired serum indicate intrathecal synthesis and are found in about 90-95% of people with multiple sclerosis.

Relapsing-remitting disease accounts for roughly 85% of presentations; primary progressive disease affects 10-15% and typically presents as progressive spastic paraparesis.

Natalizumab carries a risk of progressive multifocal leukoencephalopathy that rises with JC virus seropositivity, prior immunosuppression and treatment duration.

Neuromyelitis optica spectrum disorder is distinguished by aquaporin-4 antibodies and longitudinally extensive transverse myelitis, and is worsened by interferon beta.

Last updated: September 2026

Multiple sclerosis (MS) is the leading non-traumatic cause of permanent neurological disability in young adults. For MRCP(UK) Part 1, candidates must master the genetic and immunopathological basis of demyelination, recognize pathognomonic clinical signs, understand the McDonald diagnostic criteria as revised in 2024, evaluate disease-modifying therapies and their toxicities, and differentiate MS from neuromyelitis optica spectrum disorder (NMOSD).

  • 1. Epidemiology, Genetics & Immunopathogenesis
  • Epidemiology & Environmental Risk Factors

Demographics: Typical age of onset is 20 to 40 years ; female-to-male ratio is approximately 3:1 . Prevalence follows a latitude gradient, with significantly higher rates in temperate regions further from the equator (e.g. Scotland, Northern Europe, Canada).

Genetic Susceptibility: Polygenic inheritance with the strongest genetic association mapped to the human leukocyte antigen (HLA) Class II region: HLA-DRB1*1501 allele confers an odds ratio of approximately 3.0.

Environmental Risk Factors:

Epstein-Barr Virus (EBV): Past infection with EBV is virtually a prerequisite for developing MS; seronegativity carries a near-zero lifetime risk of MS.

Hypovitaminosis D & Sunlight: Low serum 25-hydroxyvitamin D levels and reduced ultraviolet B (UVB) exposure strongly correlate with increased incidence and relapse rates.

Cigarette Smoking: Increases risk of developing MS and accelerates progression from relapsing-remitting to secondary progressive disease.

Adolescent Obesity: Doubles the risk of developing MS via chronic low-grade systemic inflammation.

Immunopathogenesis

Autoimmune breakdown of immunological tolerance against CNS myelin sheath antigens (myelin basic protein [MBP], proteolipid protein [PLP], and myelin oligodendrocyte glycoprotein [MOG]).

Autoreactive CD4 + \text{CD4}^+ CD4 + T helper cells (pro-inflammatory Th1 secreting IFN- γ \gamma γ and Th17 secreting IL-17) and B cells undergo activation in peripheral lymphoid tissue. They adhere to brain endothelial cells via α 4 β 1 \alpha_4\beta_1 α 4 ​ β 1 ​ integrin (VLA-4) interacting with vascular cell adhesion molecule-1 (VCAM-1) and migrate across the blood-brain barrier.

In the CNS parenchyma, reactivation by local antigen-presenting cells triggers recruitment of macrophages, microglia, and CD8 + \text{CD8}^+ CD8 + cytotoxic T cells, alongside complement fixation. This causes focal perivenular inflammatory demyelination .

Although remyelination occurs early via oligodendrocyte precursor cells, persistent inflammation, loss of trophic oligodendrocytic support, and mitochondrial dysfunction ultimately produce axonal transection, cortical grey matter atrophy, and progressive neurodegeneration .

  • 2. Clinical Presentations & Pathognomonic Neurological Phenomena
  • Optic Neuritis (ON)

The presenting manifestation in ~20% of MS patients; ~50% of patients with isolated optic neuritis ultimately convert to MS within 15 years.

Symptoms: Subacute, monocular visual loss developing over hours to days, peaking at 1–2 weeks, characteristically accompanied by retro-orbital or ocular pain worsened by eye movement (due to traction on the inflamed optic nerve sheath at the annulus of Zinn).

Signs: Decreased visual acuity, marked dyschromatopsia (loss of color vision, especially red desaturation, disproportionate to acuity reduction), and a Relative Afferent Pupillary Defect (RAPD / Marcus Gunn pupil) in the affected eye.

Fundoscopy: In two-thirds of cases, the optic disc appears completely normal ( retrobulbar neuritis ; "the patient sees nothing and the doctor sees nothing"). In one-third, anterior papillitis causes disc swelling and hyperaemia.

Visual Evoked Potentials (VEP): Shows delayed P100 wave latency with preserved wave amplitude, reflecting demyelinating conduction slowing.

Internuclear Ophthalmoplegia (INO)

Caused by a demyelinating plaque within the Medial Longitudinal Fasciculus (MLF) in the dorsomedial brainstem (pons or midbrain). The MLF coordinates conjugate horizontal gaze by connecting the abducens (CN VI) nucleus to the contralateral oculomotor (CN III) medial rectus subnucleus.

Clinical Examination Findings: On attempted conjugate horizontal gaze:

Failure of adduction of the eye ipsilateral to the MLF lesion.

Coarse horizontal jerk nystagmus of the abducting contralateral eye.

Convergence is completely preserved (convergence pathways bypass the MLF and project directly to the midbrain CN III nuclei).

MRCP Exam Pearl: A bilateral INO in a young adult is virtually pathognomonic of multiple sclerosis (whereas unilateral INO in an older individual is most commonly an ischaemic stroke).

Pathognomonic Clinical Phenomena

Lhermitte's Sign: An electric shock-like sensation shooting down the spine into the limbs precipitated by neck flexion. Reflects mechanical hyperexcitability of demyelinated axons within the cervical dorsal columns.

Uhthoff's Phenomenon: Reversible, transient worsening of neurological symptoms or visual blurring occurring with an elevation in core body temperature (e.g. following a hot bath, strenuous exercise, or fever). Caused by heat-induced inactivation of voltage-gated sodium channels, abolishing the already compromised safety factor of conduction in demyelinated nerve fibres.

  • 3. Clinical Disease Courses Relapsing-Remitting MS (RRMS, ~85%)
  • │ (Acute relapses followed by full/partial remission)
  • ▼ (Over 10–20 years in untreated patients)
  • Secondary Progressive MS (SPMS)
  • (Gradual progressive accumulation of irreversible disability ± relapses)
  • Primary Progressive MS (PPMS, ~10–15%)
  • (Steady, insidious neurological decline from onset without distinct attacks;
  • typically presents as progressive spastic paraparesis in older patients, equal sex ratio)
  • 4. Diagnostic Criteria: The McDonald Criteria (2024 Revisions) & CSF Analysis

The McDonald criteria were revised in 2024 by the International Advisory Committee on Clinical Trials in MS, convened by ECTRIMS and the National MS Society, and published in The Lancet Neurology in September 2025. They supersede the 2017 criteria but retain the same core architecture, diagnosing MS by demonstrating Dissemination in Space (DIS) and Dissemination in Time (DIT) while excluding alternative diagnoses:

Diagnostic Requirement McDonald Imaging & Laboratory Criteria

Dissemination in Space (DIS) Demonstrated by ≥ 1 \ge 1 ≥ 1 T2-hyperintense lesion ( ≥ 3 mm \ge 3\text{ mm} ≥ 3 mm diameter) in at least 2 of the 4 MS-typical CNS anatomical locations :; 1. Periventricular: Adjacent to the lateral ventricles (oriented perpendicularly along deep medullary venules, termed "Dawson's fingers" ); 2. Cortical or Juxtacortical: Involving or directly abutting the cerebral cortex; 3. Infratentorial: Brainstem, cerebellar peduncles, or cerebellar hemispheres; 4. Spinal Cord: Intramedullary, typically occupying < 2 < 2 < 2 vertebral segments and < 50 % < 50\% < 50% of cord cross-section

Dissemination in Time (DIT) Demonstrated by any of the following:; 1. Subsequent clinical attack affecting a distinct anatomical site; 2. Simultaneous presence of both asymptomatic gadolinium-enhancing and non-enhancing T2 lesions on a single baseline MRI scan; 3. A new T2 or gadolinium-enhancing lesion on a follow-up MRI scan compared to baseline; 4. Positive CSF-specific Oligoclonal Bands (OCBs) : Under 2017 revisions, presence of CSF-specific OCBs satisfies the DIT requirement in patients with typical CIS meeting DIS!

Cerebrospinal Fluid (CSF) Analysis

Oligoclonal Bands (OCBs): Evaluated by isoelectric focusing (IEF) of paired CSF and serum samples. Pattern 2 (positive) : Two or more distinct IgG oligoclonal bands identified in the CSF that are completely absent in matched serum , indicating intrathecal synthesis of clonal immunoglobulins (present in > 95 % > 95\% > 95% of established MS).

Cell Count & Biochemistry: Mild lymphocytic pleocytosis ( < 50 cells/ μ L < 50\text{ cells/}\mu\text{L} < 50 cells/ μ L ); protein is normal or mildly elevated ( < 1.0 g/L < 1.0\text{ g/L} < 1.0 g/L ). Warning: A CSF cell count > 50 cells/ μ L > 50\text{ cells/}\mu\text{L} > 50 cells/ μ L or presence of neutrophils strongly argues against MS and suggests NMOSD, sarcoidosis, or CNS infection.

What Changed in the 2024 Revisions

Older revision material still teaches the 2017 criteria verbatim, so the differences are worth holding separately:

2024 revision Practical effect

The optic nerve is recognised as a fifth anatomical region for dissemination in space, alongside periventricular, cortical/juxtacortical, infratentorial and spinal cord Optic neuritis with a demonstrable optic nerve lesion now contributes directly to DIS rather than being excluded

The central vein sign and paramagnetic rim lesions are accepted as supportive imaging biomarkers Helps separate genuine demyelinating lesions from small-vessel ischaemic white matter change in older patients

The kappa free light chain index in cerebrospinal fluid is accepted alongside oligoclonal bands as evidence of intrathecal synthesis An automated, quantitative alternative where isoelectric focusing is unavailable

A unified framework across relapsing and progressive courses and across the whole lifespan , from paediatric to late-onset disease Removes the separate primary progressive MS diagnostic pathway of the 2017 criteria

The bedrock facts are unchanged and remain the ones most often tested: oligoclonal bands present in cerebrospinal fluid but absent from a paired serum sample indicate intrathecal immunoglobulin synthesis and are found in about 90-95% of people with MS, and matched bands in both compartments simply reflect a systemic inflammatory process rather than MS.

  • 5. Treatment Strategies: Relapse & Disease-Modifying Therapies (DMTs)
  • Acute Relapse Management

Indicated for acute relapses causing significant functional impairment (e.g. optic neuritis, disabling myelitis, ataxia).

First-Line Regimen: High-dose Oral Methylprednisolone 500 mg once daily for 5 days (or IV Methylprednisolone 1 g daily for 3–5 days). Co-prescribe an oral proton pump inhibitor (e.g. omeprazole 20 mg) for gastroprotection.

Mechanism & Efficacy: High-dose corticosteroids accelerate the rate of functional recovery from the acute attack by resolving perilesional inflammatory oedema and restoring blood-brain barrier integrity; corticosteroids do NOT alter the long-term progression of neurological disability .

Refractory Relapse: Plasma exchange (plasmapheresis, 5–7 cycles) for severe relapses failing high-dose corticosteroids.

Disease-Modifying Therapies (DMTs)

DMT Agent & Class Administration & Mechanism Key Toxicities, Monitoring & Prescribing Rules

Beta-Interferon (IFN- β \beta β ) & Glatiramer Acetate Subcutaneous / Intramuscular injections; downregulates MHC Class II, inhibits T-cell activation Mild efficacy (~30% relapse reduction). Flu-like symptoms, injection site necrosis, depression, transaminitis. Glatiramer is safe in pregnancy

Dimethyl Fumarate Oral twice daily; activates Nrf2 antioxidant transcriptional pathway Flushing, gastrointestinal distress, lymphopenia (requires baseline and 3-monthly full blood count; withhold if absolute lymphocyte count < 0.5 × 10 9 / L < 0.5 \times 10^9/\text{L} < 0.5 × 1 0 9 / L )

Fingolimod Oral once daily; Sphingosine-1-phosphate (S1P) receptor modulator, sequesters lymphocytes inside lymph nodes First-dose bradycardia & AV block (mandates continuous 6-hour cardiac monitoring and hourly BP/ECG on day 1); macular oedema (baseline and 3-month ophthalmic exam); VZV reactivation

Natalizumab Monthly IV infusion; recombinant monoclonal antibody against α 4 \alpha_4 α 4 ​ -integrin (VLA-4) , preventing leukocyte extravasation into CNS High efficacy (~68% relapse reduction). Major Risk: Progressive Multifocal Leukoencephalopathy (PML) caused by opportunistic JC virus (JCV) reactivation. Risk stratified by: 1. Serum anti-JCV antibody status and index; 2. Prior immunosuppressant exposure; 3. Duration of treatment ( > 2 years > 2\text{ years} > 2 years )

Ocrelizumab 6-monthly IV infusion; humanized anti-CD20 monoclonal antibody depleting mature B cells Licensed for active RRMS and early Primary Progressive MS (PPMS) . Infusion-related reactions, increased risk of respiratory tract infections, hepatitis B reactivation (screen prior to starting)

Alemtuzumab IV infusion administered in two annual pulses; anti-CD52 monoclonal antibody inducing profound lysis of T and B lymphocytes High efficacy. Severe delayed secondary autoimmunity in ~30–40%: Autoimmune thyroid disease (Graves' disease), Immune Thrombocytopenic Purpura (ITP), and Goodpasture's anti-GBM disease. Mandates monthly blood and urine monitoring for 4 years post-treatment

Symptomatic Management in Multiple Sclerosis

Spasticity: First-line: Oral baclofen (GABA-B agonist) or oral tizanidine (central α 2 \alpha_2 α 2 ​ -agonist); second-line: gabapentin, dantrolene; severe refractory cases: intrathecal baclofen pump.

Fatigue: First-line: Supervised exercise programmes; pharmacological options: amantadine (100–200 mg daily) or modafinil.

Neuropathic Pain & Dysaesthesias: Gabapentin, pregabalin, or duloxetine.

Bladder Dysfunction: Pre-treatment post-void residual volume must be checked via bladder ultrasound:

Detrusor overactivity (frequency, urgency, nocturia with low residual < 100 mL < 100\text{ mL} < 100 mL ): Treat with antimuscarinics ( tolterodine, solifenacin ) or beta-3 agonist ( mirabegron ).

Detrusor sphincter dyssynergia / incomplete emptying (residual > 100 mL > 100\text{ mL} > 100 mL ): Anticholinergics are contraindicated (precipitate acute urinary retention); institute Clean Intermittent Self-Catheterisation (CISC) .

6. Central Demyelinating Mimics: Neuromyelitis Optica Spectrum Disorder (NMOSD)

Pathogenesis: Autoimmune astrocytopathy mediated by pathogenic autoantibodies directed against Aquaporin-4 (AQP4-IgG) , a water channel densely concentrated on astrocytic end-feet at the blood-brain barrier. Binding triggers classical complement cascade activation, astrocytic swelling and lysis, with secondary granulocytic infiltration and extensive bystander demyelination.

Clinical Presentation:

Severe Optic Neuritis: Frequently bilateral, sequential or simultaneous, with poor recovery and high risk of permanent visual deficit.

Longitudinally Extensive Transverse Myelitis (LETM): Spinal cord MRI shows a contiguous, unbroken T2 hyperintense lesion extending over ≥ 3 \ge 3 ≥ 3 vertebral segments (in contrast to MS lesions which are typically short, spanning < 2 < 2 < 2 segments and located eccentrically in the cord).

Area Postrema Syndrome: Infiltration of the medullary vomiting centre at the floor of the fourth ventricle, presenting with intractable nausea, vomiting, or hiccups lasting days to weeks without an identifiable gastrointestinal cause.

Diagnostic Distinctions from Multiple Sclerosis:

Brain MRI: Frequently normal or demonstrates non-specific, non-periventricular white matter lesions.

CSF: Prominent pleocytosis often > 50 cells/ μ L > 50\text{ cells/}\mu\text{L} > 50 cells/ μ L with significant neutrophilic and eosinophilic predominance; CSF oligoclonal bands are absent in ~70–80% of patients.

Serology: AQP4-IgG seropositivity in > 75 % > 75\% > 75% ; a subset of AQP4-negative patients are seropositive for myelin oligodendrocyte glycoprotein (MOG-IgG, defining MOG-antibody-associated disease / MOGAD).

Acute and Preventive Treatment:

Acute Attacks: High-dose IV methylprednisolone (1 g daily for 5 days) followed by prompt, early Plasma Exchange (PLEX) if clinical response is incomplete.

Long-term Immunosuppressive Maintenance: Monoclonal therapies including eculizumab (terminal complement C5 inhibitor), inebilizumab (anti-CD19 B-cell depleter), satralizumab (IL-6 receptor antagonist), or rituximab (anti-CD20).

CRITICAL CONTRAINDICATION: Conventional MS disease-modifying therapies—specifically Beta-Interferon, Fingolimod, Natalizumab, and Alemtuzumab—are strictly contraindicated in NMOSD as they exacerbate the underlying disease and can precipitate catastrophic, irreversible clinical relapses.